Search Results | Cancer Research | American Association for Cancer Research

1-20 of 25

Sort by

Sort Order Select

Journal Articles

A first-in-class inhibitor of ER coregulator PELP1 targets ER+ breast cancer

Cancer Res CAN-22-0698.

DOI: https://doi.org/10.1158/0008-5472.CAN-22-0698

Published: 11 August 2022

View article

Includes: Supplementary data

Journal Articles

Abstract 5341: Mechanisms driving resistance in Group 3 and recurrent/disseminated medulloblastoma

Shiying Huang, Jie-Ling Pan, Qi Lin, YuChen Du, Jack Su, Angela Major, M. Tarek Elghetany, Kam-Man Hui, Xiaonan Li, Wan-Yee Teo

Cancer Res (2022) 82 (12_Supplement): 5341.

DOI: https://doi.org/10.1158/1538-7445.AM2022-5341

Published: 15 June 2022

View article

Journal Articles

Abstract P5-10-01: Leukemia inhibitory factor receptor inhibition reduces obesity driven progression of triple negative breast cancer

Suryavathi Viswanadhapalli, Uday P Pratap, Behnam Ebrahimi, Logan Blankenship, Jaitri Joshi, Zexuan Liu, Kristin A Altwegg, Xiaonan Li, Gangadhara R Sareddy, Bindu Santhamma, Swapna Konda, Manjeet Rao, Edward Kost, Rajeshwar R Tekmal, Hareesh B Nair, Ratna K Vadlamudi

Cancer Res (2022) 82 (4_Supplement): P5-10-01.

DOI: https://doi.org/10.1158/1538-7445.SABCS21-P5-10-01

Published: 15 February 2022

View article

Journal Articles

Abstract 634: Targeting metastatic brain germinoma using PDOX tumor models with sequential metastases

Shiying Huang, Sekar Karthik, Jack M Su, Qi Lin, YuChen Du, Ching C Lau, Adesina Adekunle, Angela Major, Kam-Man Hui, M. Tarek Elghetany, Xiaonan Li, Wan-Yee Teo

Cancer Res (2021) 81 (13_Supplement): 634.

DOI: https://doi.org/10.1158/1538-7445.AM2021-634

Published: 01 July 2021

View article

Journal Articles

Abstract 733: Significance of PELP1/SETDB1 axis in endocrine therapy resistance

Zexuan Liu, Junhao Liu, Weiwei Tang, Uday P. Pratap, Kristin A. Altwegg, Behnam Ebrahimi, Xiaonan Li, Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi

Cancer Res (2021) 81 (13_Supplement): 733.

DOI: https://doi.org/10.1158/1538-7445.AM2021-733

Published: 01 July 2021

View article

Journal Articles

Abstract 1253: Therapeutic targeting of endometrial cancer with novel LIFR inhibitor EC359

Weiwei Tang, Kumaraguruparan Ramasamy, Sureshkumar M. Pillai, Bindu Santhamma, Swapna Konda, Prabhakar P. Vekata, Logan Blankenship, Junhao Liu, Zexuan Liu, Kristin A. Altwegg, Behnam Ebrahimi, Uday P. Pratap, Xiaonan Li, Edward Kost, Gangadhara R. Sareddy, Ratna K. Vadlamudi, Hareesh B. Nair, Rajeshwar R. Tekmal, Suryavathi Viswanadhapalli

Cancer Res (2021) 81 (13_Supplement): 1253.

DOI: https://doi.org/10.1158/1538-7445.AM2021-1253

Published: 01 July 2021

View article

Journal Articles

Abstract 1237: Preclinical evaluation of ERX-41 in triple negative breast cancer

Suryavathi Viswanadhapalli, Xihui Liu, Shi-Hong Ma, Tae-Kyung Lee, Mengxing Li, Weiwei Tang, Junhao Liu, Xiaonan Li, Gangadhara R. Sareddy, Rajeshwar Rao Tekmal, Jung-Mo Ahn, Ratna K. Vadlamudi, Ganesh V. Raj

Cancer Res (2021) 81 (13_Supplement): 1237.

DOI: https://doi.org/10.1158/1538-7445.AM2021-1237

Published: 01 July 2021

View article

Journal Articles

Abstract PS17-34: Proto-oncogene PELP1 interactions with SETDB1 contribute to aberrant activation of AKT1 in breast cancer

Zexuan Liu, Junhao Liu, Weiwei Tang, Uday P. Pratap, Kristin A. Altwegg, Xiaonan Li, Suryavathi Viswanadhapalli, Ratna Vadlamudi

Cancer Res (2021) 81 (4_Supplement): PS17-34.

DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS17-34

Published: 15 February 2021

View article

Journal Articles

Abstract 4371: PELP1-TFAP2C crosstalk promotes endocrine resistance in breast cancer cells

Junhao Liu, Suryavathi Viswanadhapalli, Mengxing Li, Uday P. Pratap, Weiwei Tang, Zexuan Liu, Yiliao Luo, Kristin A. Altwegg, Xiaonan Li, Gangadhara R. Sareddy, Rajeshwar R. Tekmal, Ratna K. Vadlamudi

Cancer Res (2020) 80 (16_Supplement): 4371.

DOI: https://doi.org/10.1158/1538-7445.AM2020-4371

Published: 15 August 2020

View article

Journal Articles

Abstract 562: Novel combination therapy for treating TNBC using LIFR and HDAC Inhibitors

Suryavathi Viswanadhapalli, Mengxing Li, Bindu Santhamma, Uday P. Pratap, Yiliao Luo, Junhao Liu, Kristin A. Altwegg, Xiaonan Li, Ahmed Gulzar, Hui Yan, Zhenming Xu, Andrew Brenner, Gangadhara R. Sareddy, Manjeet K. Rao, Rajeshwar R. Tekmal, Hareesh B. Nair, Klaus J. Nickisch, Ratna K. Vadlamudi

Cancer Res (2020) 80 (16_Supplement): 562.

DOI: https://doi.org/10.1158/1538-7445.AM2020-562

Published: 15 August 2020

View article

Journal Articles

Abstract 6220: KDM1A inhibition sensitizes glioblastoma cells to temozolomide therapy through DNA damage and apoptosis pathway modulation

Bridgitte E. Palacios, Prabhakar Pitta Venkata, Yihong Chen, Salvador Alejo, Yi He, Suryavathi Viswanadhapalli, Uday Pratap, Junhao Liu, Xiaonan Li, Takayoshi Suzuki, Siyuan Zheng, Andrew Brenner, Ratna Vadlamudi, Gangadhara Sareddy

Cancer Res (2020) 80 (16_Supplement): 6220.

DOI: https://doi.org/10.1158/1538-7445.AM2020-6220

Published: 15 August 2020

View article

Journal Articles

Abstract P6-04-14: The role of PELP1-TFAP2C crosstalk in mediating endocrine-therapy-resistance in breast cancer

Junhao Liu, Suryavathi Viswanadhapalli, Mengxing Li, Uday P Pratap, Yiliao Luo, Kristin A Altwegg, Xiaonan Li, Gangadhara R Sareddy, Rajeshwar R Tekmal, Ratna K Vadlamudi

Cancer Res (2020) 80 (4_Supplement): P6-04-14.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-P6-04-14

Published: 15 February 2020

View article

Journal Articles

Abstract P3-11-08: Targeting LIFR enhances the activity of HDAC inhibitors for the treatment of triple negative breast cancer

Suryavathi Viswanadhapalli, Mengxing Li, Bindu Santhamma, Uday P Pratap, Yiliao Luo, Junhao Liu, Kristin A Altwegg, Xiaonan Li, Hui Yan, Zhenming Xu, Andrew Brenner, Gangadhara R Sareddy, Rajeshwar R Tekmal, Hareesh B Nair, Klaus J Nickisch, Ratna K Vadlamudi

Cancer Res (2020) 80 (4_Supplement): P3-11-08.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-P3-11-08

Published: 15 February 2020

View article

Journal Articles

Abstract 3485: PELP1 is a novel mediator of medulloblastoma progression

Yiliao Luo, Gangadhara Reddy Sareddy, Uday P. Pratap, Mengxing Li, Junhao Liu, Prabhakar Pitta-Venkata, Suryavathi Viswanadhapalli, Xiaonan Li, Manjeet Rao, Rajeshwar Rao Tekmal, Ratna K. Vadlamudi

Cancer Res (2019) 79 (13_Supplement): 3485.

DOI: https://doi.org/10.1158/1538-7445.AM2019-3485

Published: 01 July 2019

View article

Journal Articles

Abstract 280: Synthetic lethality of KDM1A and mTOR inhibitors: A novel combination therapy for endometrial cancer

Prabhakar Pitta-Venkata, Bridgitte Palacios, Yihong Chen, Suryavathi Viswanadhapalli, Uday P. Pratap, Yiliao Luo, Mengxing Li, Kristin Altwegg, Xiaonan Li, Takayoshi Suzuki, Rajeshwar Rao Tekmal, Edward Kost, Gangadhara Reddy Sareddy

Cancer Res (2019) 79 (13_Supplement): 280.

DOI: https://doi.org/10.1158/1538-7445.AM2019-280

Published: 01 July 2019

View article

Journal Articles

Abstract LB-069: Identification of personalized active agents in pediatric medulloblastoma through high-throughput drug screening in matching pairs of patient derived orthotopic xenograft neurosphere and monolayer cells

Lin Qi, Yuchen Du, Goeun Bae, Mari Mari, Frank Braun, Holly Lindsay, Huiyuan Zhang, Sibo Zhao, Sarah Injac, Patricia Baxter, Jack Su, Michael Mancini, Oliver Hampton, William Parsons, Mural Chintagumpala, Clifford Stephan, Peter Davies, Xiaonan Li

Cancer Res (2018) 78 (13_Supplement): LB-069.

DOI: https://doi.org/10.1158/1538-7445.AM2018-LB-069

Published: 01 July 2018

View article

Journal Articles

Abstract 1309: Network as a biomarker to predict drug candidates: Mapping driver dysregulated target networks onto pharmacologic data-derived drug networks identifies cardiac glycosides as the potential treatment of Group 3 medulloblastomas

Lei Huang, Sarah Garrett Injac, Xiaonan Li, Adesina Adekunle, Hong Zhao, Ching Lau, Stephen Wong

Cancer Res (2018) 78 (13_Supplement): 1309.

DOI: https://doi.org/10.1158/1538-7445.AM2018-1309

Published: 01 July 2018

View article

Journal Articles

Abstract 146: KDM1A inhibition is effective in reducing stemness and treating triple-negative breast cancer

Mei Zhou, Suryavathi Viswanadhapalli, Mengxing Li, Xiaonan Li, Takayoshi Suzuki, Rajeshwar R. Tekmal, Andrew Brenner, Ratna K. Vadlamudi, Gangadhara R. Sareddy

Cancer Res (2018) 78 (13_Supplement): 146.

DOI: https://doi.org/10.1158/1538-7445.AM2018-146

Published: 01 July 2018

View article

Journal Articles

Abstract 2422: The lysine demethylase KDM1A inhibition attenuates hypoxic responses in glioblastoma

Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Mei Zhou, Yiliao Luo, Xiaonan Li, Jinyou Liu, Aleksandra Gruslova, Takayoshi Suzuki, Andrew Brenner

Cancer Res (2018) 78 (13_Supplement): 2422.

DOI: https://doi.org/10.1158/1538-7445.AM2018-2422

Published: 01 July 2018

View article

Journal Articles

Abstract 2483: Estrogen receptor beta enhances chemotherapy response in GBM

Mei Zhou, Gangadhara R. Sareddy, Jinyou Liu, Mengxing Li, Suryavathi Viswanadhapalli, Xiaonan Li, Rajeshwar R Tekmal, Andrew Brenner, Ratna K. Vadlamudi

Cancer Res (2018) 78 (13_Supplement): 2483.

DOI: https://doi.org/10.1158/1538-7445.AM2018-2483

Published: 01 July 2018

View article

NARROW

A first-in-class inhibitor of ER coregulator PELP1 targets ER+ breast cancer

Abstract 5341: Mechanisms driving resistance in Group 3 and recurrent/disseminated medulloblastoma

Abstract P5-10-01: Leukemia inhibitory factor receptor inhibition reduces obesity driven progression of triple negative breast cancer

Abstract 634: Targeting metastatic brain germinoma using PDOX tumor models with sequential metastases

Abstract 733: Significance of PELP1/SETDB1 axis in endocrine therapy resistance

Abstract 1253: Therapeutic targeting of endometrial cancer with novel LIFR inhibitor EC359

Abstract 1237: Preclinical evaluation of ERX-41 in triple negative breast cancer

Abstract PS17-34: Proto-oncogene PELP1 interactions with SETDB1 contribute to aberrant activation of AKT1 in breast cancer

Abstract 4371: PELP1-TFAP2C crosstalk promotes endocrine resistance in breast cancer cells

Abstract 562: Novel combination therapy for treating TNBC using LIFR and HDAC Inhibitors

Abstract 6220: KDM1A inhibition sensitizes glioblastoma cells to temozolomide therapy through DNA damage and apoptosis pathway modulation

Abstract P6-04-14: The role of PELP1-TFAP2C crosstalk in mediating endocrine-therapy-resistance in breast cancer

Abstract P3-11-08: Targeting LIFR enhances the activity of HDAC inhibitors for the treatment of triple negative breast cancer

Abstract 3485: PELP1 is a novel mediator of medulloblastoma progression

Abstract 280: Synthetic lethality of KDM1A and mTOR inhibitors: A novel combination therapy for endometrial cancer

Abstract LB-069: Identification of personalized active agents in pediatric medulloblastoma through high-throughput drug screening in matching pairs of patient derived orthotopic xenograft neurosphere and monolayer cells

Abstract 1309: Network as a biomarker to predict drug candidates: Mapping driver dysregulated target networks onto pharmacologic data-derived drug networks identifies cardiac glycosides as the potential treatment of Group 3 medulloblastomas

Abstract 146: KDM1A inhibition is effective in reducing stemness and treating triple-negative breast cancer

Abstract 2422: The lysine demethylase KDM1A inhibition attenuates hypoxic responses in glioblastoma

Abstract 2483: Estrogen receptor beta enhances chemotherapy response in GBM

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only